Search Within

Shanu Modi

  1. "Molecular Imaging and Therapy Service"
Formats
  1. Meeting Abstract (15)
  2. Journal Article (14)
  3. Review (1)
Groups
  1. Breast Medicine Service (30)
  2. Department of Medicine (30)
  3. Molecular Imaging and Therapy Service (30)
  4. Radiology, Department of (30)
  5. Solid Tumor Oncology Division (30)
  6. Survivorship Research (23)

More Groups

People
  1. Clifford Hudis (17)
  2. Komal Jhaveri (12)
  3. Larry Norton (12)
  4. Chau Dang (10)
  5. Gabriela Chiosis (10)
  6. Mark Dunphy (10)

More People

Years
  1. 2024 (2)
  2. 2022 (1)
  3. 2021 (2)
  4. 2020 (2)
  5. 2019 (6)
  6. 2017 (3)

More Years

Publications
  1. Cancer Research (5)
  2. Journal of Clinical Oncology (5)
  3. Annals of Oncology (2)
  4. Clinical Cancer Research (2)
  5. International Journal of Radiation Oncology, Biology, Physics (2)
  6. Breast Cancer Research and Treatment (1)

More Publications

Publishers
  1. American Association for Cancer Research (7)
  2. American Society of Clinical Oncology (6)
  3. Elsevier Inc. (4)
  4. Oxford University Press (3)
  5. American Medical Association (1)
  6. American Society for Biochemistry and Molecular Biology (1)

More Publishers

Results (30)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Tumor epichaperome expression using (124)I PU-H71 PET (PU-PET) as a biomarker of response for PU-H71 plus nab-paclitaxel in HER2 negative (HER2-) metastatic breast cancer (MBC)
    Meeting Abstract

    Jhaveri, K.; Dunphy, M.; Wang, R.; Comen, E.; Fornier, M.; Moynahan, M. E.; Bromberg, J.; Ma, W.; Patil, S.; Taldone, T.; more...
    Cancer Research (2019)

    Fulltext@MSK | Save
  • Phase II study of weekly paclitaxel with trastuzumab and pertuzumab in patients with human epidermal growth receptor 2 overexpressing metastatic breast cancer: 5-year follow-up
    Journal Article

    Wang, R.; Smyth, L. M.; Iyengar, N.; Chandarlapaty, S.; Modi, S.; Jochelson, M.; Patil, S.; Norton, L.; Hudis, C. A.; Dang, C. T.
    The Oncologist (2019)

    Fulltext@MSK | Save
  • Chaperome heterogeneity and its implications for cancer study and treatment
    Review

    Wang, T.; Rodina, A.; Dunphy, M. P.; Corben, A.; Modi, S.; Guzman, M. L.; Gewirth, D. T.; Chiosis, G.
    Journal of Biological Chemistry (2019)

    Fulltext@MSK | Save
  • Phase II study of gemcitabine (G), trastuzumab (H), and pertuzumab (P) for HER2-positive metastatic breast cancer (MBC) after prior pertuzumab-based therapy
    Meeting Abstract

    Iyengar, N. M.; Smyth, L. M.; Lake, D.; Gucalp, A.; Singh, J. C.; Traina, T. A.; DeFusco, P. A.; Dickler, M. N.; Fornier, M. N.; Goldfarb, S. B.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Phase II study of gemcitabine, trastuzumab, and pertuzumab for HER2-positive metastatic breast cancer after prior pertuzumab-based therapy
    Meeting Abstract

    Iyengar, N. M.; Smyth, L. M.; Lake, D.; Gucalp, A.; Singh, J. C.; Traina, T. A.; Defusco, P.; Dickler, M. N.; Fornier, M. N.; Goldfarb, S. B.; more...
    Annals of Oncology (2017)

    Fulltext@MSK | Save
  • Phase II study of gemcitabine, trastuzumab, and pertuzumab for HER2-Positive metastatic breast cancer after prior pertuzumab-based therapy
    Meeting Abstract

    Iyengar, N. M.; Smyth, L.; Lake, D.; Gucalp, A.; Singh, J. C.; Traina, T. A.; DeFusco, P.; Dickler, M. N.; Fornier, M. N.; Goldfarb, S.; more...
    Cancer Research (2017)

    Fulltext@MSK | Save
  • Phase II study of gemcitabine, trastuzumab, and pertuzumab for HER2-positive metastatic breast cancer after prior pertuzumab-based therapy
    Meeting Abstract

    Iyengar, N. M.; Smyth, L.; Lake, D.; Gucalp, A.; Singh, J.; Traina, T. A.; Defusco, P.; Dickler, M. N.; Fornier, M.; Goldfarb, S.; more...
    Annals of Oncology (2016)

    Fulltext@MSK | Save
  • The epichaperome is an integrated chaperome network that facilitates tumour survival
    Journal Article

    Rodina, A.; Wang, T.; Yan, P.; Gomes, E. D.; Dunphy, M. P. S.; Pillarsetty, N.; Koren, J. 3rd; Gerecitano, J. F.; Taldone, T.; Zong, H.; more...
    Nature (2016)

    Fulltext@MSK | Save
  • Development of a noninvasive assay to determine drug concentration in tumor during hsp90 inhibitor therapy
    Meeting Abstract

    Taldone, T.; Pillarsetty, N.; Dunphy, M. P. S.; Gerecitano, J. F.; Caldas-Lopes, E.; Beattie, B.; Peter, R. I.; Kang, Y. L.; Rodina, A.; Yan, P.; more...
    Cancer Research (2015)

    Fulltext@MSK | Save
  • Phase I study of LJM716, BYL719, and trastuzumab in patients (pts) with HER2-amplified (HER2+) metastatic breast cancer (MBC)
    Meeting Abstract

    Shah, P. D.; Chandarlapaty, S.; Dickler, M. N.; Ulaner, G.; Zamora, S. J.; Sterlin, V.; Iasonos, A.; Coughlin, C. M.; Morozov, A.; Ero, J.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save